Garcia-Foncillas J

Full Professor

Universidad Autónoma de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

ORCID

Google Scholar

About

Garcia-Foncillas J is a Full Professor at Universidad Autónoma de Madrid, Spain. His research focuses on molecularly guided cancer care, treatment patterns in acute myeloid leukemia, and the role of biomarkers in oncology. He has contributed to significant studies regarding performance status in metastatic cancer and therapeutic targets in various cancer types.

Garcia-Foncillas J

Research Interests

Explore related searches

Contact this professor

About

Articles (29)

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.

Derivation and External Validation of Objective Performance Status Among Patients With Metastatic Cancer

Overcoming barriers in biomarker testing. Letter to the Editor regarding: “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”, by A. Bayle et al.

Natriuretic peptides: Another tool for the management of cancer?

Delphi consensus for the third-line treatment of metastatic colorectal cancer.

Correction to: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells (British Journal of Cancer, (2024), 130, 8, (1402-1413), 10.1038/s41416-024-02649-z)

Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare

Affinity of PET-MRI Tracers for Hypoxic Cells in Breast Cancer: A Systematic Review

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment

Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer

A complex microRNA regulatory network may control the HCP5/UTP3/c-Myc/VAMP3 signaling axis

Biological mechanisms of cancer-related fatigue in breast cancer survivors after treatment: a scoping review

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Cancer-Related Fatigue and Circulating Biomarkers in Breast Cancer Survivors

Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells

Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV

A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy.

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer

Cancer in the 21&lt;sup&gt;st&lt;/sup&gt; Century: a Multidisciplinary Perspective

Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors

Galectin-1, a novel promising target for outcome prediction and treatment in SCLC

ISG15 as a prognostic biomarker in solitary fibrous tumour

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

Collaborators (8)

ISABEL CANO FERRI

Enrique Aranda Aguilar

Laura del Puerto Nevado

Keith Abrams

María Jesús Fernández Aceñero

Arancha Cebrián Aranda

Javier Martinez-Useros

pedro villarejo campos

How do I reach out?

Meet Kite AI

Cancer in the 21<sup>st</sup> Century: a Multidisciplinary Perspective